- Home
- CABA vs PLX Comparison
CABA vs PLX Comparison
Compare CABA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- PLX
- Stock Information
- Founded
- CABA 2017
- PLX 1993
- Country
- CABA United States
- PLX United States
- Employees
- CABA N/A
- PLX N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CABA Health Care
- PLX Health Care
- Exchange
- CABA Nasdaq
- PLX Nasdaq
- Market Cap
- CABA 149.3M
- PLX 127.4M
- IPO Year
- CABA 2019
- PLX 1998
- Fundamental
- Price
- CABA $1.71
- PLX $1.61
- Analyst Decision
- CABA Strong Buy
- PLX Strong Buy
- Analyst Count
- CABA 7
- PLX 1
- Target Price
- CABA $14.29
- PLX $15.00
- AVG Volume (30 Days)
- CABA 1.3M
- PLX 526.6K
- Earning Date
- CABA 08-07-2025
- PLX 08-14-2025
- Dividend Yield
- CABA N/A
- PLX N/A
- EPS Growth
- CABA N/A
- PLX N/A
- EPS
- CABA N/A
- PLX 0.05
- Revenue
- CABA N/A
- PLX $59,764,000.00
- Revenue This Year
- CABA N/A
- PLX $10.00
- Revenue Next Year
- CABA N/A
- PLX $83.13
- P/E Ratio
- CABA N/A
- PLX $33.43
- Revenue Growth
- CABA N/A
- PLX 0.18
- 52 Week Low
- CABA $0.99
- PLX $0.82
- 52 Week High
- CABA $6.26
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CABA 57.70
- PLX 57.34
- Support Level
- CABA $1.26
- PLX $1.41
- Resistance Level
- CABA $1.56
- PLX $1.52
- Average True Range (ATR)
- CABA 0.12
- PLX 0.07
- MACD
- CABA 0.00
- PLX 0.02
- Stochastic Oscillator
- CABA 92.78
- PLX 74.38
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.